Why PDS Biotechnology Stock Is Soaring Today


PDS Biotechnology Corp PDSB shares are up nearly 30% Monday after the company announced a 100% clinical response in cervical cancer patients in preliminary data from the IMMUNOCERV Phase 2 clinical trial. PDS Biotechnology also reported better-than-expected earnings results.

What Happened: PDS presented updated clinical data from the ongoing IMMUNOCERV Phase 2 clinical trial at the 37th Annual Meeting for the Society for Immunotherapy of Cancer. The study is investigating PDS0101 in combination with standard-of-care chemoradiotherapy (CRT) for the potential treatment of cervical cancer.

100% of patients treated with the combination of PDS0101 and CRT had a clinical response with tumor shrinkage greater than 60% at mid-point evaluation by MRI. 89% of patients demonstrated a complete response on day 170 and a one-year disease-free survival. 

"We believe this study also provides further confirmation that PDS0101 induces the right type, quality, and potency of killer T cells in humans that may translate to effective treatment of cervical cancer," said Dr. Frank Bedu-Addo, CEO of PDS Biotechnology.

PDS also reported a third-quarter net loss of 26 cents per share, which beat average analyst estimates for a loss of 28 cents per share. The company ended the quarter with approximately $71.6 million in cash, according to Benzinga Pro

PDS is a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease.

PDSB Price Action: PDS has a 52-week high of $8.47 and a 52-week low of $2.89.

The stock was up 29.8% at $7.27 at time of publication.

Photo: Konstantin Kolosov from Pixabay.

Market News and Data brought to you by Benzinga APIs
Posted In: MoversTrading Ideaswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!